Avandia panel agenda released

FDA released the dates and agenda for a previously announced panel to discuss the cardiovascular safety of diabetes drug Avandia rosiglitazone from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). On July 13-14, the joint meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management advisory committees will review data from the RECORD trial of Avandia, as well as observational and health claims data and a meta-analysis of controlled trials of the drug. Additionally, FDA will present its meta-analysis of data from several trials of Actos pioglitazone from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). ...